Please wait a minute...
Journal of Molecular and Clinical Medicine  2018, Vol. 1 Issue (2): 77-84    DOI: 10.31083/j.jmcm.2018.02.004
Research article Previous articles | Next articles
Differential mechanism of action of the CK1$\varepsilon $ inhibitor GSD0054
Irene Lagunes1, Elva Martín-Batista1, Gastón Silveira-Dorta1, Miguel X. Fernandes1, 2, José M. Padrón1, *()
1 BioLab, Instituto Universitario de Bio-Orgánica "Antonio González" (IUBO-AG), Centro de Investigaciones Biomédicas de Canarias (CIBICAN), Universidad de La Laguna, C/ Astrofísico Francisco Sánchez 2, 38206 La Laguna, Spain
2 Centro de Química da Madeira, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal
Download:  PDF(965KB)  ( 323 ) Full text   ( 32 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

In the current study, we explored for the first time, the mechanism of action of the new Casein kinase 1 $\varepsilon$ (CK1$\varepsilon$) selective inhibitor GSD0054. Although GSD0054 behaved as a selective CK1$\varepsilon $ inhibitor in enzymatic assays, we studied whether this inhibitory activity also occurred inside the cells. The effects of GSD0054 on $\beta $-catenin expression and disruption of cell cycle progression were studied in the human breast cancer cell lines MDA-MB-453 ($\beta $-catenin negative) and T-47D ($\beta $-catenin positive). We also performed molecular modeling studies using computational docking against CK1$\varepsilon $ to explain and predict the mechanism of action of this compound. Moreover, the commercially available CK1$\varepsilon $ inhibitor PF-4800567 and the CK1$\delta $/$\varepsilon $ inhibitors PF-670462 and IC261 were also studied for comparison purposes.GSD0054 showed anti-proliferative activity against MDA-MB-453 and T-47D cells despite the fact that MDA-MB-453 cells do not possess active $\beta$-catenin. However, selective cell killing occurred in the more resistant, $\beta $-catenin active, T-47D cells. CK1$\varepsilon $ was confirmed as a cellular target, although other targets or alternative mechanisms of action could possibly explain the anti-proliferative activity in MDA-MB-453 cells.

Key words:  Synthetic lethality      Casein kinase inhibitors      Wnt/beta-catenin      Anti-beta-amino alcohols      Breast cancer     
Submitted:  24 December 2018      Revised:  03 January 2018      Accepted:  05 January 2018      Published:  20 April 2018     
*Corresponding Author(s):  José M. Padrón     E-mail:  jmpadron@ull.es

Cite this article: 

Irene Lagunes, Elva Martín-Batista, Gastón Silveira-Dorta, Miguel X. Fernandes, José M. Padrón. Differential mechanism of action of the CK1$\varepsilon $ inhibitor GSD0054. Journal of Molecular and Clinical Medicine, 2018, 1(2): 77-84.

URL: 

https://jmcm.imrpress.com/EN/10.31083/j.jmcm.2018.02.004     OR     https://jmcm.imrpress.com/EN/Y2018/V1/I2/77

Fig.1.  Chemical structures of ICK1$\varepsilon $ GSD0054 (1) and PF-4800567 (2); and ICK1$\delta $/$\varepsilon $ PF-670462 (3) and IC 261 (4).

Table 1  Anti-proliferative activity (GI$_{50})$ of ICK1$\varepsilon $ drugs in MDA-MB-453 ($\beta $-catenin negative) and T-47D ($\beta $-catenin positive) cell lines$^{\rm a}$.
MDA-MB-453 T-47D Rb
GSD0054 (1) 2.4 士 0.5 17 士 1.7 7.1
PF-4800567 (2) 58 士 11 79 士 6.4 1.4
PF-670462 (3) 42 士 6.5 11 士 2.0 3.8
IC 261 (4) 0.087 士 0.040 0.032 士 0.007 2.7
Table 2  Anti-proliferative activity (GI$_{50})$ of ICK1$\varepsilon $ in SW1573 and SW1573/P-gp cell lines$^{\rm a}$.
- Verapamil 十 Verapamil
SW1573 SW1573/P-gp Rfb SW1573 SW1573/P-gp Rf
GSD0054(1) 16 士 2 16 士 3 1 20 士 1 17 士 4 0.9
PF-4800567(2) 76 士 26 48 士 24 0.6 85 士 14 51 士 25 0.6
PF-670462 (3) 19 士 3 19 士 8 1 21 士 7 19 士 6 0.9
IC 261 (4) 0.25 士 0.03 0.79 士 0.10 3.2 0.35 士 0.03 0.86 士 0.42 2.5
Paclitaxel 0.0029 士 0.0009 4 士 0.5 1379 0.0030 士 0.0015 0.0036 士 0.0015 1.2
Fig.2.  Dose-response curves of SW1573 and SW1573/P-gp cells treated with ICK1$\varepsilon $ 1-4 for 48 h.

Fig.3.  Expression of $\beta $-catenin in drug-treated T-47D cells. Cells were exposed to compounds 1-4 for 24 h at the indicated doses. C (-): MDA-MB-453, negative control; C ($+$): T-47D, positive control. $\beta $-Actin signals allowed us to normalize the experiment.

Fig.4.  Cell cycle histograms of MDA-MB-453 and T-47D untreated cells (control) and cells treated (drug concentration in $\mu $M) for 24 h with compounds 1-4 at the indicated doses.

Fig.5.  ROS production increase in MDA-MB-453 and T-47D cells treated with drug (dose in $\mu $M) for 48 h with compounds 1-4 at the indicated concentrations. LD (low dose) of 1, 10, 10, 0.1 and HD (high dose) of 10, 100, 100, 1 $\mu $M for 1-4, respectively.

Table 3  Docking scores of drugs 1-4 against CK1$\varepsilon $.
Compound Score (kcal/mol)
GSD0054(1) -5.8
PF-4800567 (2) -10.8
PF-670462 (3) -6.5
IC 261 (4) -5.9
[1] Vielhaber E, Virshup DM . Casein kinase I: from obscurity to center stage. IUBMB Life, 2001; 51:73-78.
doi: 10.1080/15216540117461 pmid: 11463166
[2] Knippschild U, Wolff S, Giamas G, Brockschmidt C, Wittau M, Würl PU, Eismann T , St$\ddot{o}$ter M. The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie, 2005; 28:508-514.
[3] Knippschild U, Krüger M, Richter J, Xu P, García-Reyes B, Peifer C, Halekotte J, Bakulev V, Bischof J . The CK1 family: contribution to cellular stress response and its role in carcinogenesis. Front Oncol, 2014; 4:96.
doi: 10.3389/fonc.2014.00096 pmid: 4032983
[4] Yang WS, Stockwell BR . Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biol, 2008; 9:R92.
doi: 10.1186/gb-2008-9-6-r92 pmid: 2481424
[5] Price MA . CK1, there's more than one: casein kinase I family members in Wnt and Hedgehog signalling. Genes Dev, 2006; 20:399-410.
[6] Kim SY, Dunn IF, Firestein R, Gupta P, Wardwell L, Repich K, Schinzel AC, Wittner B, Silver SJ, Root DE, Boehm JS, Ramaswamy S, Lander ES, Hahn WC . CK1$\varepsilon $ is required for breast cancers dependent on $\beta $-catenin activity. PLoS One, 2010; 5:e8979.
doi: 10.1371/journal.pone.0008979 pmid: 20126544
[7] Cheong JK, Nguyen TH, Wang H, Tan P, Voorhoeve PM, Lee SH, Virshup DM . IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1$\delta $/$\varepsilon $ and Wnt/$\beta $-catenin independent inhibition of mitotic spindle formation. Oncogene, 2011; 30:2558-2569.
[8] Silveira-Dorta G, Sousa IJ, Fernandes MX, Martín VS, Padrón JM . Synthesis and identification of unprecedented selective inhibitors of CK1$\varepsilon $. Eur J Med Chem, 2015; 96:308-317.
doi: 10.1016/j.ejmech.2015.03.046 pmid: 25899335
[9] Silveira-Dorta G, Donadel OJ, Martín VS, Padrón JM . Direct stereoselective synthesis of enantiomerically pure anti-$\beta $-amino alcohols. J Org Chem, 2014; 79:6775-6782.
doi: 10.1002/chin.201505092
[10] Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M . Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst, 1991; 83:757-766.
[11] Gilson MK, Liu T, Baitaluk M, Nicola G, Hwang L, Chong J . BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res, 2016; 44:D0145-D1053.
doi: 10.1093/nar/gkv1072 pmid: 26481362
[12] Bradley G, Juranka PF, Ling V . Mechanism of multidrug resistance. Biochim Biophys Acta, 1988; 948:87-128.
[13] Rodriguez N, Yang J, Hasselblatt K, Liu S, Zhou Y, Rauh-Hain JA, Ng SK, Choi PW, Fong WP, Agar NY, Welch WR, Berkowitz RS, Ng SW . Casein kinase 1 epsilon interacts with mitochondrial proteins for the growth and survival of human ovarian cancer cells. EMBO Mol Med, 2012; 4:952-963.
doi: 10.1002/emmm.201101094 pmid: 22707389
[14] Behrend L, Milne DM , Stoter M, Deppert W, Campbell LE, Meek DW, Knippschild U. IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Oncogene, 2000; 19:5303-5313.
[15] Hao J, Ao A, Zhou L, Murphy CK, Frist AY, Keel JJ, Thorne CA, Kim K, Lee E, Hong CC . Selective small molecule targeting $\beta $-catenin function discovered by in vivo chemical genetic screen. Cell Rep, 2013; 4:898-904.
doi: 10.1016/j.celrep.2013.07.047 pmid: 3923627
[1] Adrián Puerta, Alexis R. Galán, Roderick Abdilla, Kaylie Demanuele, Miguel X. Fernandes, Giovanna Bosica, José M. Padrón. Naphthol-derived Betti bases as potential SLC6A14 blockers[J]. Journal of Molecular and Clinical Medicine, 2019, 2(2): 35-40.
[2] Adrián Puerta, Alexis R. Galán, Miguel X. Fernandes, José M. Padrón. Facts and myths of selective casein kinase 1 ε inhibition[J]. Journal of Molecular and Clinical Medicine, 2018, 1(4): 195-200.
[3] Amanda P. B. Albuquerque, Meritxell Balmaña, Celso A. Reis, Eduardo I.C. Beltrão. Identification of appropriate housekeeping genes for quantitative RT-PCR analysis in MDA-MB-231 and NCI-H460 human cancer cell lines under hypoxia and serum deprivation[J]. Journal of Molecular and Clinical Medicine, 2018, 1(3): 127-134.
[4] Sohvi Blatter, Nadine Stokar-Regenscheit, Ariena Kersbergen, Charlotte Guyader, Sven Rottenberg. Chemotherapy induces an immunosuppressive gene expression signature in residual BRCA1/p53-deficient mouse mammary tumors[J]. Journal of Molecular and Clinical Medicine, 2018, 1(1): 7-17.
No Suggested Reading articles found!